← Leaderboards
Darren Orton
Stemsynergy Therapeutics, Inc.
$11,188,596
Attributed
$12,173,894
Total exposure
13
Grants
10
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2010–22$2.5M$1.9M$1.3M$625K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$12,173,894 · 13
By mechanism
R44$9,699,493 · 4
R43$2,249,410 · 8
R41$224,991 · 1
Top collaborators
- Dennis Liang Fei2 shared
- Marcy Lynn Guerra1 shared
- William Russell Guerrant1 shared
Most similar at Stemsynergy Therapeutics, Inc.
Same institution · by research overlap
- Marcy Lynn Guerra$112,500
- Dennis Liang Fei$1,915,495
Others in their field
Top investigators on “Pharmaceutical Preparations”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$266,816,120
- Leonard Freedman · Leidos Biomedical Research, Inc.$240,520,687
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$196,976,947
- Lawrence Corey · Fred Hutchinson Cancer Center$196,976,947
Research focus
Pharmaceutical PreparationsMalignant NeoplasmsInhibitor/AntagonistIn VitroPre-ClinicalLeadSmall Business Innovation Research GrantIn VivoClinical TrialsPathway InteractionsClinicToxic EffectMouse ModelGrowthColorectal CancerFda ApprovedSmall MoleculeCancer CellWnt Signaling PathwayAnimal ModelLegal PatentProgramsCessation Of LifeBase
Grant awards (20)
Small Molecule N-myc Degraders as Novel Cancer Therapeutic Agents$399,999
R43 · FY2022 · CA
Development of Notch1-selective Small Molecule Inhibitor for the Treatment of Cancer$945,599
R44 · FY2021 · CA
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)$621,402
R44 · FY2020 · CA · contact PI
Small Molecule Inhibitors of Notch Activation Complex Kinase (NACK) as Novel Cancer Therapeutic Agents$399,999
R43 · FY2020 · CA
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)$1,375,997
R44 · FY2019 · CA · contact PI
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER$999,981
R44 · FY2019 · CA · contact PI
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER$999,998
R44 · FY2018 · CA · contact PI
Development of an Oral WNT inhibitor$299,999
R43 · FY2018 · CA · contact PI
Development of Notch Pathway Specific Inhibitors as Targeted Therapeutics for Cancer$299,994
R43 · FY2018 · CA · contact PI
Repurposing of Pyrvinium Pamoate for Familial Adenomatous Polyposis (FAP)$297,882
R44 · FY2018 · CA · contact PI
DEVELOPMENT OF A WNT PATHWAY INHIBITOR FOR METASTATIC COLORECTAL CANCER$1,000,000
R44 · FY2017 · CA · contact PI
Development of a WNT Inhibitor for Regenerative Healing of Burn Injuries$225,000
R43 · FY2016 · GM · contact PI
Repurposing Pyrvinium as an Orphan Drug for Familial Adenomatous Polyposis$224,991
R41 · FY2016 · CA · contact PI
Development of a LRP6 Monoclonal Antibody for Triple Negative Breast Cancer$224,968
R43 · FY2016 · CA · contact PI
Development of a WNT Inhibitor for Advanced Stage Lung Cancer$907,344
R44 · FY2015 · CA · contact PI
Development of a WNT Inhibitor for Advanced Stage Lung Cancer$592,630
R44 · FY2014 · CA · contact PI
Development of Wnt Pathway Inhibitors for Colorectal Cancer$859,094
R44 · FY2013 · CA · contact PI
Development of Wnt Pathway Inhibitors for Colorectal Cancer$1,099,566
R44 · FY2012 · CA · contact PI
Targeting stem cell populations in lung cancer by modulating the Wnt and p53 path$259,451
R43 · FY2012 · CA · contact PI
Development of Wnt Pathway Inhibitors for Colorectal Cancer$140,000
R43 · FY2010 · CA · contact PI